SPOTLIGHT: Panel advises against long-term data

An FDA advisory panel is recommending that the makers of drugs used to treat depression should not have to provide long-term data on their effectiveness. The FDA had been considering major changes in the data that would be needed to gain approval for a drug to treat depression. Report